Ameta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumorswith invasive implants

Oncologist

Volumn 20, Issue 2, 2015, Pages 151-158

  Vasconcelos, Ines ^a   Olschewski, Jessica ^a   Braicu, Ioana ^a   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adjuvant treatment; Borderline ovarian tumors; Chemotherapy; Implants; Platinum based treatment

Indexed keywords

PLATINUM; DRUG IMPLANT;

ABDOMINAL HYSTERECTOMY; ARTICLE; BORDERLINE OVARIAN TUMOR; BREAST IMPLANT; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; META ANALYSIS; OMENTECTOMY; OUTCOME ASSESSMENT; OVARY TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLICATION; SALPINGOOOPHORECTOMY; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CYSTADENOCARCINOMA, SEROUS; DRUG IMPLANT; FEMALE; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; DRUG IMPLANTS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM; TREATMENT OUTCOME;

EID: 84922704688     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0144     Document Type: Article

References (40)

1. Taylor HC. Malignantandsemi-malignant tumors of the ovary. Surg Gynecol Obstet 1929;48:204-230.
2. Kaern J, Tropé CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993;71:1810-1820.
3. Gershenson DM, Silva EG, Levy L et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998;82:1096-1103.
4. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors: Histologic features and prognosis. Cancer 1988;62: 2212-2222.
5. Leary A, Petrella MC, Pautier P et al. Adjuvant platinum-based chemotherapy for borderline serous ovarian tumorswith invasive implants. Gynecol Oncol 2014;132:23-27.
6. Sneige N, Thomison JB, Malpica A et al. Peritoneal washing cytologic analysis of ovarian serous tumors of low malignant potential to detect peritoneal implants and predict clinical outcome. Cancer Cytopathol 2012;120:238-244.
7. Anfinan N, Sait K, Ghatage P et al. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre. Arch Gynecol Obstet 2011;284:731-735.
8. Goldstein NS, Ceniza N. Ovarian micropapillary serous borderline tumors. Clinicopathologic features and outcome of seven surgically staged patients. Am J Clin Pathol 2000;114:380-386.
9. Lenhard MS, Mitterer S, Kümper C et al. Longterm follow-up after ovarian borderline tumor: Relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol 2009;145:189-194.
10. Deffieux X, Morice P, Camatte S et al. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants. Gynecol Oncol 2005;97:84-89.
11. Kokawa K, Mikami Y, Sakata H et al. Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years’ experience in the Kinki District of Japan (1990-2006). Eur J Gynaecol Oncol 2009;30:155-161.
12. Wong HF, Low JJ, Chua Y et al. Ovarian tumors of borderlinemalignancy: A reviewof 247 patients from 1991 to 2004. Int JGynecol Cancer 2007;17:342-349.
13. Park JY, Kim DY, Kim JH et al. Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol Oncol 2009; 113:75-82.
14. Laurent I, Uzan C, Gouy S et al. Results after conservative treatmentof serous borderline tumors of the ovary with amicropapillary pattern. Ann Surg Oncol 2008;15:3561-3566.
15. Camatte S, Morice P, Pautier P et al. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG 2002;109:376-380.
16. Morice P, Camatte S, Rey A et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 2003; 14:592-598.
17. Zanetta G, Rota S, Chiari S et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: A prospective study. J Clin Oncol 2001; 19:2658-2664.
18. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996;20: 1331-1345.
19. Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990;65:578-585.
20. de Nictolis M, Montironi R, Tommasoni S et al. Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, andquantitative study of 44 cases. Cancer 1992;70:152-160.
21. Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. AmJ SurgPathol 2000;24:1465-1479.
22. Akeson M, Zetterqvist BM, Dahllöf K et al. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Cancer 2008;18:453-459.
23. Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 1996;78:278-286.
24. Snider DD, Stuart GC, Nation JG et al. Evaluation of surgical staging in stage I low malignant potential ovarian tumors. Gynecol Oncol 1991;40:129-132.
25. Prat J, De Nictolis M. Serous borderline tumors of the ovary: A long-term follow-up study of 137 cases, including 18with amicropapillary patternand 20 with microinvasion. Am J Surg Pathol 2002;26: 1111-1128.
26. Longacre TA, McKenney JK, Tazelaar HD et al. Ovarian serous tumors of low malignant potential (borderline tumors): Outcome-based study of 276 patients with long-term (> or 55-year) follow-up. Am J Surg Pathol 2005;29:707-723.
27. Eichhorn JH, Bell DA, Young RH et al. Ovarian serous borderline tumors with micropapillary and cribriform patterns: A study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 1999;23:397-409.
28. Fauvet R, Demblocque E, Morice Petal. Behavior of serous borderline ovarian tumors with andwithout micropapillary patterns: Results of a Frenchmulticenter study. Ann Surg Oncol 2012;19:941-947.
29. Kane A, Uzan C, Gouy S et al. Fertility results and outcomes after pure laparoscopic management of advanced-stage serous borderline tumors of the ovary. Fertil Steril 2010;94:2891-2894.
30. De Iaco P, Ferrero A, Rosati F et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur J SurgOncol 2009;35: 643-648.
31. Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas.AmJ Surg Pathol 2001;25:419-432.
32. Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol 2005;18(suppl 2):S33-S50.
33. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. Advanced OvarianCancerTrialistsGroup. BMJ 1991;303:884-893.
34. Allen DG, Baak J, Belpomme D et al. Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol 1993;4(suppl 4):83-88.
35. Trimble EL. The NIH Consensus Conference on Ovarian Cancer: Screening, treatment, and followup. Gynecol Oncol 1994;55:S1-S3.
36. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer.Gynecol Oncol 2000;78: 269-274.
37. Winter WE III, Maxwell GL, Tian C et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2008;26:83-89.
38. Fauvet R, Boccara J, Dufournet C et al. Restaging surgery for women with borderline ovarian tumors: Results of a French multicenter study. Cancer 2004;100:1145-1151.
39. du Bois A, Ewald-Riegler N, de Gregorio N et al. Borderlinetumours oftheovary:Acohort studyofthe ArbeitsgmeinschaftGynäkologischeOnkologie (AGO) Study Group. Eur J Cancer 2013;49:1905-1914.
40. Daniela Fischerova, Michal Zikan, Pavel Dundr et al. Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors The Oncologist 2012;17:1515-1533.